0.50 / AMA PRA Category 1 Credit(s)TM 0.50 / CE for Pharmacists (0.05 CEUs)
This educational initiative is provided by CME Outfitters.
Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Alzheimer’s disease (AD) continues to be a growing health crisis. Progress has been made in our understanding of AD pathogenesis; however, there remains no currently effective treatment to delay the onset of or prevent the disease.
The pathophysiological process of AD begins many years before clinically obvious symptoms appear. In addition, the concept of a pre-symptomatic or preclinical stage of AD is gaining acceptance in the medical community. Discussion of risk factors and careful assessments of individuals 60 or older can improve recognition and help direct treatment approaches.
In this neuroscienceCME Snack, expert faculty will discuss cutting edge data that can be incorporated to meet the demands of managing complex patients in everyday clinical practice.
Physicians, pharmacists, and other health care professionals with an interest in Alzheimer’s disease
At the end of this CME/CE activity, participants should be able to:
Implement routine cognitive screening to facilitate early identification and early intervention of Alzheimer’s disease
Discuss the role and clinical utility of biomarkers and imaging for current use in the diagnosis and early intervention in AD
Discuss with colleagues the emerging science and therapies that will build tomorrow’s treatments for AD
Conflict Of Interest Disclosure Policy
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Charles B. Nemeroff, MD, PhD Leonard M. Miller Professor and Chairman Director, Center on Aging Department of Psychiatry and Behavioral Sciences Leonard M. Miller School of Medicine University of Miami Miami, FL
Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Bracket (Clintara); Gerson Lehrman Group, Inc. (GLG) Healthcare & Biomedical Council; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Total Pain Solutions (TPS); and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara);Brain & Behavior Research Foundation (BBRF) (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]); Clintara; RiverMend Health, LLC; Skyland Trail; and Xhale, Inc. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); and GratitudeAmerica, Inc. He is a stockholder of AbbVie Inc,; Bracket (Clintara); Celgene Corporation; COPKO Health, Inc.; Seattle Genetics, Inc.; Titan Pharmaceuticals, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; Bracket (Clintara); CME Outfitters, LLC; Takeda Pharmaceuticals North America, Inc.; Xhale, Inc. Dr. Nemeroff has patients for method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Anand Kumar, MD Lizzie Gilman Professor and Head Department of Psychiatry College of Medicine University of Illinois at Chicago Chicago, IL
Dr. Kumar serves as the Associate Editor of The American Journal of Geriatric Psychiatry.
Accredited Provider Disclosure
The CME Outfitters, LLC staff has nothing to disclose.
Planners' and Managers' Disclosures
Tony Graham, MD (peer reviewer) has no disclosures to report. Robert Kennedy (planning committee) has no disclosures to report. Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
AMA PRA Category 1 Credit(s)TM
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Pharmacists
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.50 contact hours (0.05 CEUs)
Universal Activity Number: 0376-0000-16-015-H01-P
Activity Type: knowledge-based
Disclosure of Unlabeled Use
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Lilly do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating in this CME/CE activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.
To obtain a certificate, participants must receive a score of 75% or better on the post-test. The post-test can be accessed at the end of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact firstname.lastname@example.org.